LifeMap Sciences (“LifeMap”), a subsidiary of AgeX Therapeutics,
Inc. (NYSE American: AGE), announced today that it has entered into
a collaboration with iCarbonX Research Shenzhen, enabling iCarbonX
to leverage LifeMap’s GeneCards® Suite platform in product
prototype design and scientific research.
LifeMap Sciences is a leading biomedical knowledgebase company
that commercializes the popular GeneCards Suite, including
GeneCards®, the Human Gene Compendium, MalaCards®, the Human
Disease Database, as well as sophisticated analytic tools based on
the comprehensive suite. LifeMap’s user base includes more than
four million researchers world-wide and its customers include
top-tier pharma and biotech customers. The GeneCards Suite has been
developed in collaboration with the Weizmann Institute of Science
in Israel.
LifeMap Sciences has recently started offering access to its
integrated knowledgebase and analytic tools via specialized
application program interfaces or APIs for aims spanning drug
discovery and repurposing, point of care solutions, next generation
sequencing interpretation, internal bioinformatics platforms and
enrichment of precision medicine solutions. These APIs enable
companies like iCarbonX to integrate knowledge from the GeneCards
Suite Knowledgebase into their existing processes and research
pipelines.
“LifeMap offers sophisticated tools for integrated analysis and
big data-driven biological informatic associations,” said Hancheng
Zheng, the Director of Bioinformatics and AI Platform at iCarbonX.
“Its GeneCards Suite significantly improves the efficacy of
scientific researchers and life science professionals, and it has
been helpful to us in product prototype design and scientific
research.”
“LifeMap’s integrated knowledgebase enables organizations to
economically and rapidly acquire and implement integrated
biomedical data solutions into their existing platform,” commented
Yaron Guan Golan, CEO of LifeMap Sciences. “iCarbonX is one of our
most sophisticated users in this area, and is using machine
learning and big data analysis solutions aimed at improving health
and well-being. As a leader in its field, we are proud to be part
of iCarbonX’s partner network and to empower their research with
our knowledgebase data and solutions.”
For inquiries regarding the use of GeneCards Knowledgebase Suite
data and tools, contact Yaron Guan Golan, CEO at LifeMap Sciences:
yg@lifemapsc.com.
About LifeMap Sciences
LifeMap Sciences is a life sciences technology company that
offers integrated, streamlined solutions empowering life scientists
worldwide in conducting cutting-edge basic, clinical and applied
biomedical research. LifeMap’s products are used in more than 3,000
institutions including academia, research hospitals, patent
offices, and leading biopharma and diagnostic companies. Operations
worldwide are carried out from our offices in California,
Massachusetts, New Jersey, Tel Aviv, and Hong Kong.
For more information, please visit https://www.lifemapsc.com
About iCarbonX
Digital health pioneer iCarbonX is creating the new global
standard for health, wellness and healthcare by building the
platform for digitizing, analyzing, and understanding life. With
breakthrough technologies, deep multi-omics, artificial
intelligence and experiential data, it delivers products, services
and solutions for both partners and consumers to help people
optimize their lives, from wellness, skincare and fitness, to
health, nutrition and prevention, to health care, condition
management and outcome achievement.
For more information, please visit http://www.icarbonx.com
About the Weizmann Institute of Science and GeneCards
The Weizmann Institute of Science in Rehovot, Israel, is one of
the world’s top-ranking multidisciplinary research institutions.
Noted for its wide-ranging exploration of the natural and exact
sciences, the Institute is home to scientists, postdoctoral
fellows, Ph.D. and M.Sc. students, and scientific, technical and
administrative staff. In addition, visiting scientists and their
families – over 500 from 35 countries are regularly hosted at the
Institute. Particular excellence in bioinformatics and systems
biology is manifested, among others, in the GeneCards project,
initiated in 1996, under the leadership of Prof. Doron Lancet of
the Dept. of Molecular Genetics, until recently Head of the Crown
Human Genome Center. The team, led by Marilyn Safran, continuously
innovates to maintain GeneCards as the leading integrated human
gene compendium. GeneCards® is a registered trademark of Yeda
Research and Development Co. Ltd.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s
delivery technology to stably engraft PureStem cell therapies and
slowly release iTR molecules in the body. AgeX is aggressively
developing its core product pipeline for use in the clinic to
extend human healthspan, and is seeking opportunities to form
licensing and partnership agreements around its broad IP estate and
proprietary technology platforms for non-core clinical
applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, Facebook and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of
AgeX’s Information Statement filed as an exhibit to its
Registration Statement on Form 10 with the Securities and Exchange
Commissions (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date
of this release, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190307005245/en/
Media Contact for AgeX:Bill DouglassGotham Communications,
LLCbill@gothamcomm.com(646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024